Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection

Seonheui Lee, Jeongae Go, Soolienah Rhiu, R. Doyle Stulting, Min Lee, Sunyoung Jang, Sangmoo Lee, Hyung Joon Kim, Eui Sang Chung, Sooyoung Kim, KyoungYul Seo

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Purpose: To evaluate the complications of cosmetic wide conjunctivectomy and postoperative topical mitomycin C application with or without bevacizumab injection. Design: Cross-sectional cohort study. Methods: Medical records of 1713 consecutive subjects who received cosmetic wide conjunctivectomy plus postoperative topical mitomycin C by a single surgeon at a single center with or without bevacizumab injection from November 2007 to May 2010 were reviewed. A telephone interview was conducted with 557 of the subjects who could be contacted and agreed to participate in the study. Complications, recurrences, and patient satisfaction were the main outcome measures. Results: A total of 1713 consecutive patients underwent cosmetic wide conjunctivectomy to treat conjunctival hyperemia. Ocular diagnoses in the medical records at the time of surgery included hyperemia (8.8%), pterygium (14.0%), dry eye (3.5%), pinguecula (1.5%), and conjunctival disorder (23.3%). For the remaining 48.9% of subjects, the diagnosis was not mentioned, or the surgical procedure was for cosmetic purposes. Patients were followed for a mean of 10.9 months (range, 0-30.3 months). The overall complication rate was 82.9%, of which 55.6% were considered severe (fibrovascular conjunctival tissue proliferation, 43.8%; scleral thinning, 4.4%; scleral thinning with calcified plaques, 6.2%; intraocular pressure elevation, 13.1%; diplopia, 3.6%; and recurrence of hyperemic conjunctiva, 28.1%). Conclusions: Cosmetic wide conjunctivectomy plus postoperative topical mitomycin C with or without bevacizumab injection has a high rate of complications and reoperations.

Original languageEnglish
JournalAmerican Journal of Ophthalmology
Volume156
Issue number3
DOIs
Publication statusPublished - 2013 Jan 1

Fingerprint

Mitomycin
Cosmetics
Injections
Hyperemia
Medical Records
Pinguecula
Pterygium
Recurrence
Diplopia
Conjunctiva
Patient Satisfaction
Intraocular Pressure
Reoperation
Cohort Studies
Cross-Sectional Studies
Outcome Assessment (Health Care)
Bevacizumab
Interviews

All Science Journal Classification (ASJC) codes

  • Ophthalmology

Cite this

Lee, Seonheui ; Go, Jeongae ; Rhiu, Soolienah ; Stulting, R. Doyle ; Lee, Min ; Jang, Sunyoung ; Lee, Sangmoo ; Kim, Hyung Joon ; Chung, Eui Sang ; Kim, Sooyoung ; Seo, KyoungYul. / Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection. In: American Journal of Ophthalmology. 2013 ; Vol. 156, No. 3.
@article{f7788e24f73d4bdc84b8ee15c5438fe7,
title = "Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection",
abstract = "Purpose: To evaluate the complications of cosmetic wide conjunctivectomy and postoperative topical mitomycin C application with or without bevacizumab injection. Design: Cross-sectional cohort study. Methods: Medical records of 1713 consecutive subjects who received cosmetic wide conjunctivectomy plus postoperative topical mitomycin C by a single surgeon at a single center with or without bevacizumab injection from November 2007 to May 2010 were reviewed. A telephone interview was conducted with 557 of the subjects who could be contacted and agreed to participate in the study. Complications, recurrences, and patient satisfaction were the main outcome measures. Results: A total of 1713 consecutive patients underwent cosmetic wide conjunctivectomy to treat conjunctival hyperemia. Ocular diagnoses in the medical records at the time of surgery included hyperemia (8.8{\%}), pterygium (14.0{\%}), dry eye (3.5{\%}), pinguecula (1.5{\%}), and conjunctival disorder (23.3{\%}). For the remaining 48.9{\%} of subjects, the diagnosis was not mentioned, or the surgical procedure was for cosmetic purposes. Patients were followed for a mean of 10.9 months (range, 0-30.3 months). The overall complication rate was 82.9{\%}, of which 55.6{\%} were considered severe (fibrovascular conjunctival tissue proliferation, 43.8{\%}; scleral thinning, 4.4{\%}; scleral thinning with calcified plaques, 6.2{\%}; intraocular pressure elevation, 13.1{\%}; diplopia, 3.6{\%}; and recurrence of hyperemic conjunctiva, 28.1{\%}). Conclusions: Cosmetic wide conjunctivectomy plus postoperative topical mitomycin C with or without bevacizumab injection has a high rate of complications and reoperations.",
author = "Seonheui Lee and Jeongae Go and Soolienah Rhiu and Stulting, {R. Doyle} and Min Lee and Sunyoung Jang and Sangmoo Lee and Kim, {Hyung Joon} and Chung, {Eui Sang} and Sooyoung Kim and KyoungYul Seo",
year = "2013",
month = "1",
day = "1",
doi = "10.1016/j.ajo.2013.01.035",
language = "English",
volume = "156",
journal = "American Journal of Ophthalmology",
issn = "0002-9394",
publisher = "Elsevier USA",
number = "3",

}

Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection. / Lee, Seonheui; Go, Jeongae; Rhiu, Soolienah; Stulting, R. Doyle; Lee, Min; Jang, Sunyoung; Lee, Sangmoo; Kim, Hyung Joon; Chung, Eui Sang; Kim, Sooyoung; Seo, KyoungYul.

In: American Journal of Ophthalmology, Vol. 156, No. 3, 01.01.2013.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Cosmetic regional conjunctivectomy with postoperative mitomycin C application with or without bevacizumab injection

AU - Lee, Seonheui

AU - Go, Jeongae

AU - Rhiu, Soolienah

AU - Stulting, R. Doyle

AU - Lee, Min

AU - Jang, Sunyoung

AU - Lee, Sangmoo

AU - Kim, Hyung Joon

AU - Chung, Eui Sang

AU - Kim, Sooyoung

AU - Seo, KyoungYul

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Purpose: To evaluate the complications of cosmetic wide conjunctivectomy and postoperative topical mitomycin C application with or without bevacizumab injection. Design: Cross-sectional cohort study. Methods: Medical records of 1713 consecutive subjects who received cosmetic wide conjunctivectomy plus postoperative topical mitomycin C by a single surgeon at a single center with or without bevacizumab injection from November 2007 to May 2010 were reviewed. A telephone interview was conducted with 557 of the subjects who could be contacted and agreed to participate in the study. Complications, recurrences, and patient satisfaction were the main outcome measures. Results: A total of 1713 consecutive patients underwent cosmetic wide conjunctivectomy to treat conjunctival hyperemia. Ocular diagnoses in the medical records at the time of surgery included hyperemia (8.8%), pterygium (14.0%), dry eye (3.5%), pinguecula (1.5%), and conjunctival disorder (23.3%). For the remaining 48.9% of subjects, the diagnosis was not mentioned, or the surgical procedure was for cosmetic purposes. Patients were followed for a mean of 10.9 months (range, 0-30.3 months). The overall complication rate was 82.9%, of which 55.6% were considered severe (fibrovascular conjunctival tissue proliferation, 43.8%; scleral thinning, 4.4%; scleral thinning with calcified plaques, 6.2%; intraocular pressure elevation, 13.1%; diplopia, 3.6%; and recurrence of hyperemic conjunctiva, 28.1%). Conclusions: Cosmetic wide conjunctivectomy plus postoperative topical mitomycin C with or without bevacizumab injection has a high rate of complications and reoperations.

AB - Purpose: To evaluate the complications of cosmetic wide conjunctivectomy and postoperative topical mitomycin C application with or without bevacizumab injection. Design: Cross-sectional cohort study. Methods: Medical records of 1713 consecutive subjects who received cosmetic wide conjunctivectomy plus postoperative topical mitomycin C by a single surgeon at a single center with or without bevacizumab injection from November 2007 to May 2010 were reviewed. A telephone interview was conducted with 557 of the subjects who could be contacted and agreed to participate in the study. Complications, recurrences, and patient satisfaction were the main outcome measures. Results: A total of 1713 consecutive patients underwent cosmetic wide conjunctivectomy to treat conjunctival hyperemia. Ocular diagnoses in the medical records at the time of surgery included hyperemia (8.8%), pterygium (14.0%), dry eye (3.5%), pinguecula (1.5%), and conjunctival disorder (23.3%). For the remaining 48.9% of subjects, the diagnosis was not mentioned, or the surgical procedure was for cosmetic purposes. Patients were followed for a mean of 10.9 months (range, 0-30.3 months). The overall complication rate was 82.9%, of which 55.6% were considered severe (fibrovascular conjunctival tissue proliferation, 43.8%; scleral thinning, 4.4%; scleral thinning with calcified plaques, 6.2%; intraocular pressure elevation, 13.1%; diplopia, 3.6%; and recurrence of hyperemic conjunctiva, 28.1%). Conclusions: Cosmetic wide conjunctivectomy plus postoperative topical mitomycin C with or without bevacizumab injection has a high rate of complications and reoperations.

UR - http://www.scopus.com/inward/record.url?scp=84882241782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84882241782&partnerID=8YFLogxK

U2 - 10.1016/j.ajo.2013.01.035

DO - 10.1016/j.ajo.2013.01.035

M3 - Article

VL - 156

JO - American Journal of Ophthalmology

JF - American Journal of Ophthalmology

SN - 0002-9394

IS - 3

ER -